52 results about "Xenobiotic" patented technology

The invention provides a system and methods for the determination of the pharmacogenomic phenotype of any individual or group of individuals, ideally classified to a discrete, specific and defined pharmacogenomic population(s) using machine learning and population structure. Specifically, the invention provides a system that integrates several subsystems, including (1) a system to classify an individual as to pharmacogenomic cohort status using properties of underlying structural elements of the human population based on differences in the variations of specific genes that encode proteins and enzymes involved in the absorption, distribution, metabolism and excretion (ADME) of drugs and xenobiotics, (2) the use of a pre-trained learning machine for classification of a set of electronic health records (EHRs) as to pharmacogenomic phenotype in lieu of genotype data contained in the set of EHRs, (3) a system for prediction of pharmacological risk within an inpatient setting using the system of the invention, (4) a method of drug discovery and development using pattern-matching of previous drugs based on pharmacogenomic phenotype population clusters, and (5) a method to build an optimal pharmacogenomics knowledge base through derivatives of private databases contained in pharmaceutical companies, biotechnology companies and academic research centers without the risk of exposing raw data contained in such databases. Embodiments include pharmacogenomic decision support for an individual patient in an inpatient setting, and optimization of clinical cohorts based on pharmacogenomic phenotype for clinical trials in drug development.

The present invention discloses a method of calcification-resisting modifying for the heterologous biology tissue material, in the method the tannic acid solution is used to immerse the tissue; the concentration of the tannic acid is between 1 and 6%, the pH value of the solution is between 4.0 and 6.0, the immersing temperature is between 18 and 32 DEG C, and the immersing time is between 24 and 96 hour. The method of the invention can simultaneously crosslink the collagen fiber, the elastic fiber and glycosaminoglycan in the cell epimatrix of the tissue material, reduce the degradation when the tissue is implanted to the body, compensate the insufficiency that the pentanedial only crosslinks the collagen fiber and remarkably increase the calcification-resisting capability of the material; has the effect of antibacterial and reducing the protein antigenicity, and helps to increase the calcification-resisting capability and bioavailability of the material. The intercrossed tissue material has the advantages of good biostability, reinforced biomechanical property and long service lifetime.

The invention discloses a biovalve crosslinking method. The method includes introducing an unsaturated group to heterogeneous biological tissues such as porcine active valves, pig pericardia and bovine pericardia into through active groups on the biological tissues such as a carboxyl group, a hydroxyl group, an amino group and a sulfhydryl group reacting with an unsaturated group-containing compound to obtain an unsaturated group-modified biological tissue, and then obtaining a crosslinked biological tissue by radical polymerization. The biological tissue obtained by the crosslinking method has excellent collagen and elastin stability, blood compatibility, no cytotoxicity, good mechanical properties, anti-calcification capability and low inflammatory response.

The present invention provides methods and compositions for balancing electron reduction potentials of formulations in a manner that reduces susceptibility to changes from xenobiotics. The present invention also provides novel compositions of matter based on structuring from a mobile nucleotide integral to its architecture.

The invention provides a non-invasive technique for the detection and quantification of the immune repertoire, in a biological sample containing a plurality of distinct cell populations. Methods are conducted using sequencing technology to detect and enumerate immune repertoire within a heterogeneous biological sample.

The present invention relates to a chronotherapeutic combination pharmaceutical formulation, which is designed to control the release of each ingredient of the combined drug in a predetermined rate based on the principle of the so-called chronotherapy and xenobiotics, where drugs are administered to exhibit pharmacological activities at predetermined time intervals. The formulations of the present invention comprise a dihydropyridine, and a statin, as active ingredients. The formulations are structured and arranged such that the respective release rates of the above ingredients can be controlled, thereby reducing or preventing antagonistic effects and side effects resulting from the interaction of the above ingredients, while maintaining the synergistic effect, and providing easy medication.

The invention relates to a detection of four sites of single nucleotide polymorphism (SNP) which are arranged on two human body xenobiotics metabolismenzyme genes including ABCG2 and CYP2E1 and which are associated with the systemic lupus erythematosus (SLE). The invention also can use four sites of single nucleotide polymorphism (SNP) to forecast the liability of systemic lupus erythematosus and to determine the drug to cure the systemic lupus erythematosus. The information provided by the invention is helpful for preventing systemic lupus erythematosus (SLE) and for developing effective new treatments.

The invention discloses a method of simply, easily and efficiently lowering the content of magnesium in salt lake brine. The method comprises the following steps of adding excessive water-soluble hydroxide in the salt lake brine, and uniformly stirring, wherein the molar weight of introduced hydroxy radicals is at least 1.5 times of theoretical amount for completely precipitating Mg<2+>; standing for precipitation, and carrying out solid-liquid separation, wherein a filtrate is brine with low magnesium content. The method provided by the invention is simple in treatment technology and convenient to operate and can be implemented in the salt lake field, so that the transportation cost is greatly lowered. By adopting the method, excessive xenobiotics cannot be introduced in a salt lake region, and magnesium hydroxide as a by-product is also a resource with a great value and is environment-friendly; and the magnesium removal efficiency is high, the lithium loss is low, the filtrate after solid-liquid separation can be directly used for preparing lithium carbonate and is particularly suitable for batch magnesium-lithium separation of plateau salt lakes in a large scale.

The invention discloses application of GAD67 and an epigenetic mark thereof which serve as early markers of fetal-original bipolar affective disorder susceptibility, and belongs to the field of gene functions and application. Research results show that in hippocampi and white blood cells of fetal rats in a pregnancy ethanol exposure group, compared with a normal control group, the methylation level of a GAD67 promoter region is significantly reduced, and the gene expression of the GAD67 promoter region is improved; after growing up, the rats in the xenobiotic exposure group show high hypothalamic-pituitary-adrenal (HPA) axis stress sensibility and bipolar affective disorder susceptibility under the condition of chronic unpredictable stress. Therefore, risks that offspring have bipolar affective disorder after growing up can be judged by detecting the epigenetic modification and expression levels of the GAD67 genes in the white blood cells of fetal blood/umbilical cord blood. Research bases are provided for an early warning technology of the fetal-original bipolar affective disorder, and meanwhile, possibilities are provided for effectively treating the fetal-original bipolar affective disorder in early stages.

An emulsion of perfluoroorganic compounds (PFOC) comprises a rapidly eliminable perfluorocarbon (PFC) and a slowly eliminable perfluorinated cyclic tertiary amine, perfluoro-N-4-(methylcyclohexyl)-piperidine and additionally comprises not less then three rapidly eliminable and three slowly eliminable PFOC admixtures with the critical temperature of dissolution in hexane (CTDH) close to that of main PFOC. The PFOC emulsion is stabilized with a polyoxyethylene-polyoxypropylene copolymer having low viscosity to provide high dynamic oxygen capacity and enhancing oxygen delivery to tissues. To prepare the emulsion the stabilizing agent is heated up to 75° C., all components are saturated with carbon dioxide gas to minimize the reactogenicity in intravessel injection as a means of compensation for mass blood loses, perfusion of organs cut of blood flow, treating air-and fat embolism, obliterating vascular injuries of extremities and preventing toxic injuries caused by various xenobiotics.

The purpose of the present invention is to provide: detergent-free decellularization method of xenogenic biological tissues for human body surgery, in which the pericardium, blood vessels, other membrane-like biological tissues, and the like are decellularized so as to have resistance to mechanical property loss, mineralization and immune reactivity; and decellularized tissue. Decellularized tissue, according to the present invention, when compared to untreated tissue, has greater calcification reduction in vivo, blood compatibility and biocompatibility improvement, tissue thickness reduction, and increases in tensile strength, kink resistance and the like.